$204.90

FREE
SHIPPING

100% MONEY
BACK GUARANTEE

ONLINE
SUPPORT 24/7

Available on backorder. No lead time available. Please request a quote.
Sku CI01353_100_G
Chem Impex
Get Bulk Quote

Product Information

Product Name
Boc-L-a-tert-butylglycine
Brand Name
Chem Impex
Product Number
01353
CAS
62965-35-9
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
2734668
IUPAC Name
(2S)-3,3-dimethyl-2-(2-methylpropan-2-yl)oxycarbonylaminobutanoic acid
InChI Key
LRFZIPCTFBPFLX-SSDOTTSWSA-N
SMILES
CC(C)(C)C@@H(C(=O)O)NC(=O)OC(C)(C)C

Application

Boc-L-a-tert-butylglycine is widely utilized in research focused on:

Peptide Synthesis: This compound serves as a protective group in the synthesis of peptides, allowing chemists to selectively modify amino acids without affecting others, which is crucial for creating complex biological molecules.

Drug Development: Its unique structure makes it valuable in the design of pharmaceuticals, particularly in optimizing the properties of drug candidates, enhancing their stability and bioavailability.

Bioconjugation: Researchers use it to create bioconjugates, linking biomolecules with drugs or imaging agents, which is essential in targeted therapy and diagnostics in medicine.

Protein Engineering: The compound is employed in modifying proteins to study their functions and interactions, aiding in the development of novel enzymes and therapeutic proteins.

Research in Neuroscience: Its derivatives are explored in studies related to neurotransmitter systems, contributing to the understanding of neurological disorders and potential treatments.

References Data Source From Pubchem

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations

Publication Name: Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
Publication Date: 2022-08-30
DOI: 10.1007/s00044-022-02951-6

Correction to: Medulloblastoma cerebrospinal fluid reveals metabolites and lipids indicative of hypoxia and cancer-specific RNAs

Publication Name: Acta Neuropathologica Communications
Publication Date: 2022-04-22
DOI: 10.1186/s40478-022-01326-7|10.1186/s40478-022-01368-x

An Orally Available Clinical Candidate to Treat Covid-19

Publication Name: Synfacts
Publication Date: 2022-01-18
DOI: 10.1055/s-0041-1737252

Peptide Macrocyclization Through Palladium-Catalyzed Late-Stage C-H ActivationC-H activation

Publication Name: Methods in molecular biology (Clifton, N.J.)
Publication Date: 2022
DOI: 10.1007/978-1-0716-1689-5_3

Nirmatrelvir

Publication Name: Pharmaceutical Substances
Publication Date: 2022